Foropafant | SR-27417 | CAS#136468-36-5 | PAF inhibitor

MedKoo Cat#: 326907 | Name: Foropafant

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Foropafant, also known as SR-27417; SR-27417A, is a potent platelet activating factor (PAF) inhibitor potentially for the treatment of asthma and allergic rhinitis (AR). SR 27417 inhibits in a dose-dependent manner the hypotensive effect of PAF in rats. It protected rats with an ED50 value of 6 +/- 2 micrograms/kg (n = 6), when given i.v., 1 min before PAF administration. PAF plays a major role in anaphylactic shock. SR 27417 may be an effective prophylactic as well as a potent curative drug in this pathology.

Chemical Structure

Foropafant

CAS#136468-36-5 (free base)

Theoretical Analysis

MedKoo Cat#: 326907

Name: Foropafant

CAS#: 136468-36-5 (free base)

Chemical Formula: C28H40N4S

Exact Mass: 464.2974

Molecular Weight: 464.72

Elemental Analysis: C, 72.37; H, 8.68; N, 12.06; S, 6.90

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 385.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

136468-36-5 (free base) 136470-45-6 (fumarate)

Synonym

Foropafant; SR-27417; SR 27417; SR27417;

IUPAC/Chemical Name

3-(((2-(Dimethylamino)ethyl)(4-(2,4,6-triisopropylphenyl)-2-thiazolyl)amino)methyl)pyridine

InChi Key

VVBFISAUNSXQGZ-UHFFFAOYSA-N

InChi Code

InChI=1S/C28H40N4S/c1-19(2)23-14-24(20(3)4)27(25(15-23)21(5)6)26-18-33-28(30-26)32(13-12-31(7)8)17-22-10-9-11-29-16-22/h9-11,14-16,18-21H,12-13,17H2,1-8H3

SMILES Code

CC(C1=C(C2=CSC(N(CC3=CC=CN=C3)CCN(C)C)=N2)C(C(C)C)=CC(C(C)C)=C1)C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 464.72 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Bélanger C, Elimam H, Lefebvre J, Borgeat P, Marleau S. Involvement of endogenous leukotriene B4 and platelet-activating factor in polymorphonuclear leucocyte recruitment to dermal inflammatory sites in rats. Immunology. 2008 Jul;124(3):295-303. doi: 10.1111/j.1365-2567.2007.02767.x. Epub 2008 Jan 24. PubMed PMID: 18217950; PubMed Central PMCID: PMC2440823. 2: Sobhani I, Canedo S, Alchepo B, Vissuzaine C, Chevalier C, Buyse M, Moizo L, Laigneau JP, Mignon M, Lewin JM, Bado A. Putative effect of Helicobacter pylori and gastritis on gastric acid secretion in cat. Am J Physiol Gastrointest Liver Physiol. 2002 Apr;282(4):G727-34. PubMed PMID: 11897633. 3: Cheminade C, Gautier V, Hichami A, Allaume P, Le Lannou D, Legrand AB. 1-O-alkylglycerols improve boar sperm motility and fertility. Biol Reprod. 2002 Feb;66(2):421-8. PubMed PMID: 11804958. 4: Queralt M, Brazís P, Merlos M, de Mora F, Puigdemont A. In vitro inhibitory effect of rupatadine on histamine and TNF-alpha release from dispersed canine skin mast cells and the human mast cell line HMC-1. Inflamm Res. 2000 Jul;49(7):355-60. PubMed PMID: 10959557. 5: Bastos da Silva M, Delaunois A, Gustin P, Godeau JM, Lekeux P. In vitro inhibitory effect of SR 27417, a potent platelet-activating factor (PAF) receptor antagonist, on the PAF-induced bovine platelet aggregation. Vet Res. 2000 Mar-Apr;31(2):267-72. PubMed PMID: 10779205. 6: Berthou C, Bourge JF, Zhang Y, Soulié A, Geromin D, Denizot Y, Sigaux F, Sasportes M. Interferon-gamma-induced membrane PAF-receptor expression confers tumor cell susceptibility to NK perforin-dependent lysis. Blood. 2000 Apr 1;95(7):2329-36. PubMed PMID: 10733503. 7: Gómez FP, Marrades RM, Iglesia R, Roca J, Barberà JA, Chung KF, Rodriguez-Roisin RM. Gas exchange response to a PAF receptor antagonist, SR 27417A, in acute asthma: a pilot study. Eur Respir J. 1999 Sep;14(3):622-6. PubMed PMID: 10543285. 8: Stack WA, Jenkins D, Vivet P, Hawkey CJ. Lack of effectiveness of the platelet-activating factor antagonist SR27417A in patients with active ulcerative colitis: a randomized controlled trial. The Platelet Activating Factor Antagonist Study Group in Ulcerative Colitis. Gastroenterology. 1998 Dec;115(6):1340-5. PubMed PMID: 9834260. 9: Gómez FP, Roca J, Barberà JA, Chung KF, Peinado VI, Rodriguez-Roisin R. Effect of a platelet-activating factor (PAF) antagonist, SR 27417A, on PAF-induced gas exchange abnormalities in mild asthma. Eur Respir J. 1998 Apr;11(4):835-9. PubMed PMID: 9623685. 10: Kotelevets L, Noë V, Bruyneel E, Myssiakine E, Chastre E, Mareel M, Gespach C. Inhibition by platelet-activating factor of Src- and hepatocyte growth factor-dependent invasiveness of intestinal and kidney epithelial cells. Phosphatidylinositol 3'-kinase is a critical mediator of tumor invasion. J Biol Chem. 1998 Jun 5;273(23):14138-45. PubMed PMID: 9603913. 11: Hichami A, Duroudier V, Leblais V, Vernhet L, Le Goffic F, Ninio E, Legrand A. Modulation of platelet-activating-factor production by incorporation of naturally occurring 1-O-alkylglycerols in phospholipids of human leukemic monocyte-like THP-1 cells. Eur J Biochem. 1997 Dec 1;250(2):242-8. PubMed PMID: 9428670. 12: Negro Alvarez JM, Miralles López JC, Ortiz Martínez JL, Abellán Alemán A, Rubio del Barrio R. Platelet-activating factor antagonists. Allergol Immunopathol (Madr). 1997 Sep-Oct;25(5):249-58. Review. PubMed PMID: 9395010. 13: Herbert JM, Castro-Faria-Neto HC, Barbosa-Filho JM, Cordeiro RS, Tibiriça E. Pharmacological evidence for the putative existence of two different subtypes of PAF receptors on platelets and leukocytes; studies with yangambin. J Lipid Mediat Cell Signal. 1997 Sep;17(1):1-14. PubMed PMID: 9302650. 14: Bernat A, Hoffmann P, Dumas A, Serradeil-le Gal C, Raufaste D, Herbert JM. V2 receptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs. J Pharmacol Exp Ther. 1997 Aug;282(2):597-602. PubMed PMID: 9262320. 15: Evans DJ, Barnes PJ, Cluzel M, O'Connor BJ. Effects of a potent platelet-activating factor antagonist, SR27417A, on allergen-induced asthmatic responses. Am J Respir Crit Care Med. 1997 Jul;156(1):11-6. PubMed PMID: 9230719. 16: Croci T, Landi M, Emonds-Alt X, Le Fur G, Maffrand JP, Manara L. Role of tachykinins in castor oil diarrhoea in rats. Br J Pharmacol. 1997 Jun;121(3):375-80. PubMed PMID: 9179376; PubMed Central PMCID: PMC1564694. 17: Tiller PR, Cunniff J, Land AP, Schwartz J, Jardine I, Wakefield M, Lopez L, Newton JF, Burton RD, Folk BM, Buhrman DL, Price P, Wu D. Drug quantitation on a benchtop liquid chromatography-tandem mass spectrometry system. J Chromatogr A. 1997 May 30;771(1-2):119-25. PubMed PMID: 9210315. 18: Thielman NM, Marcinkiewicz M, Sarosiek J, Fang GD, Guerrant RL. Role of platelet-activating factor in Chinese hamster ovary cell responses to cholera toxin. J Clin Invest. 1997 Apr 15;99(8):1999-2004. PubMed PMID: 9109445; PubMed Central PMCID: PMC508025. 19: Herbert JM, Bernat A, Tibiriça E. Effect of SR 27417, a novel PAF antagonist on antigen-induced hypotension in the rat. J Lipid Mediat Cell Signal. 1997 Jan;15(2):115-23. PubMed PMID: 9034959. 20: Buhrman DL, Price PI, Rudewiczcor PJ. Quantitation of SR 27417 in human plasma using electrospray liquid chromatography-tandem mass spectrometry: A study of ion suppression. J Am Soc Mass Spectrom. 1996 Nov;7(11):1099-105. doi: 10.1016/S1044-0305(96)00072-4. PubMed PMID: 24203071.